DNMT3A mutation is associated with increased age and adverse outcome in adult T-cell acute lymphoblastic leukemia - PubMed (original) (raw)
. 2019 Aug;104(8):1617-1625.
doi: 10.3324/haematol.2018.197848. Epub 2019 Jan 17.
Jonathan Bond 1 2 3, Stéphane Leprêtre 4, Carlos Graux 5, Mario Bargetzi 6 7, Ludovic Lhermitte 1, Guillaume Hypolite 1, Thibaut Leguay 8, Yosr Hicheri 9, Gaëlle Guillerm 10, Karin Bilger 11, Véronique Lhéritier 12, Mathilde Hunault 13, Françoise Huguet 14, Yves Chalandon 6 15, Norbert Ifrah 13, Elizabeth Macintyre 1, Hervé Dombret 16, Vahid Asnafi 1, Nicolas Boissel 17
Affiliations
- PMID: 30655366
- PMCID: PMC6669163
- DOI: 10.3324/haematol.2018.197848
DNMT3A mutation is associated with increased age and adverse outcome in adult T-cell acute lymphoblastic leukemia
Jonathan Bond et al. Haematologica. 2019 Aug.
Abstract
The prognostic implications of DNMT3A genotype in T-cell acute lymphoblastic leukemia are incompletely understood. We performed comprehensive genetic and clinico-biological analyses of T-cell acute lymphoblastic leukemia patients with DNMT3A mutations treated during the GRAALL-2003 and -2005 studies. Eighteen of 198 cases (9.1%) had DNMT3A alterations. Two patients also had DNMT3A mutations in non-leukemic cell DNA, providing the first potential evidence of age-related clonal hematopoiesis in T-cell acute lymphoblastic leukemia. DNMT3A mutation was associated with older age (median 43.9 years vs 29.4 years, P<0.001), immature T-cell receptor genotype (53.3% vs 24.4%, _P_=0.016) and lower remission rates (72.2% mutated vs 94.4% non-mutated, _P_=0.006). DNMT3A alterations were significantly associated with worse clinical outcome, with higher cumulative incidence of relapse (HR 2.33, 95% CI: 1.05-5.16, _P_=0.037) and markedly poorer event-free survival (HR 3.22, 95% CI: 1.81-5.72, P<0.001) and overall survival (HR 2.91, 95% CI: 1.56-5.43, _P_=0.001). Adjusting for age as a covariate, or restricting the analysis to patients over 40 years, who account for almost 90% of _DNMT3A_-mutated cases, did not modify these observations. In multivariate analysis using the risk factors that were used to stratify treatment during the GRAALL studies, DNMT3A mutation was significantly associated with shorter event-free survival (HR 2.33, 95% CI: 1.06 - 4.04, _P_=0.02). Altogether, these results identify DNMT3A genotype as a predictor of aggressive T-cell acute lymphoblastic leukemia biology. The GRAALL-2003 and -2005 studies were registered at http://www.ClinicalTrials.gov as #NCT00222027 and #NCT00327678, respectively.
Copyright© 2019 Ferrata Storti Foundation.
Figures
Figure 1.
DNMT3A mutations in T-cell acute lymphoblastic leukemia. (A) Schematic representation of the 21 mutations detected in this study. Further patient-specific details are provided in Online Supplementary Table S3. (B) Comparison of the mutational genotypes of DNMT3A altered (n=18) and DNMT3A wild-type (n=180) T-cell acute lymphoblastic leukemia. Percentage frequencies in each group are depicted. Functional categories are listed in bold.
Figure 2.
Evidence of DNMT3A mutations in non-leukemic DNA. (A) Direct sequencing of DNMT3A exons 14 and 15, NOTCH1 and NRAS in diagnostic (left panels) and remission (right panels) samples. (B) Mutational assessment of DNA extracted from leukemic and non-leukemic fractions of samples from patients with T-cell acute lymphoblastic leukemia. Sequencing results of DNMT3A and NOTCH1 in leukemic (left panels) and non-leukemic (right panels) DNA are shown. Cases are numbered according to the listing in Online Supplementary Table S3.
Figure 3.
DNMT3A mutation correlates with poor outcome in T-cell acute lymphoblastic leukemia. Comparisons of outcomes for patients with (n=18) and without (n=180) DNMT3A mutations are shown for: (A) cumulative incidence of relapse; (B) event-free survival; and (C) overall survival. The 5-year results were as follows: cumulative incidence of relapse 53.9% mutated vs. 28.7% non-mutated; event-free survival 27.8% mutated vs. 61.0% non-mutated; overall survival 38.8% mutated vs. 68.7% non-mutated. P values are indicated.
Figure 4.
DNMT3A genotype predicts outcome in the age group of patients at risk of mutation. Comparisons of outcomes for patients with (n=16) and without (n=34) mutations in patients >40 years are shown for: (A) cumulative incidence of relapse; (B) event-free survival; and (C) overall survival. The 5-year results were as follows: cumulative incidence of relapse 58.3% mutated vs. 21.7% non-mutated; event-free survival, 25.0% mutated vs. 56.7% non-mutated; overall survival 37.5% mutated vs. 62.1% non-mutated. P values are indicated.
Similar articles
- An early thymic precursor phenotype predicts outcome exclusively in HOXA-overexpressing adult T-cell acute lymphoblastic leukemia: a Group for Research in Adult Acute Lymphoblastic Leukemia study.
Bond J, Marchand T, Touzart A, Cieslak A, Trinquand A, Sutton L, Radford-Weiss I, Lhermitte L, Spicuglia S, Dombret H, Macintyre E, Ifrah N, Hamel JF, Asnafi V. Bond J, et al. Haematologica. 2016 Jun;101(6):732-40. doi: 10.3324/haematol.2015.141218. Epub 2016 Mar 4. Haematologica. 2016. PMID: 26944475 Free PMC article. Clinical Trial. - Early Response-Based Therapy Stratification Improves Survival in Adult Early Thymic Precursor Acute Lymphoblastic Leukemia: A Group for Research on Adult Acute Lymphoblastic Leukemia Study.
Bond J, Graux C, Lhermitte L, Lara D, Cluzeau T, Leguay T, Cieslak A, Trinquand A, Pastoret C, Belhocine M, Spicuglia S, Lheritier V, Leprêtre S, Thomas X, Huguet F, Ifrah N, Dombret H, Macintyre E, Boissel N, Asnafi V. Bond J, et al. J Clin Oncol. 2017 Aug 10;35(23):2683-2691. doi: 10.1200/JCO.2016.71.8585. Epub 2017 Jun 12. J Clin Oncol. 2017. PMID: 28605290 Clinical Trial. - Clinicopathologic Effect of DNMT3A Mutation in Adult T-Cell Acute Lymphoblastic Leukemia.
Aref S, El Menshawy N, El-Ghonemy MS, Zeid TA, El-Baiomy MA. Aref S, et al. Clin Lymphoma Myeloma Leuk. 2016 Jan;16(1):43-8. doi: 10.1016/j.clml.2015.11.003. Epub 2015 Dec 1. Clin Lymphoma Myeloma Leuk. 2016. PMID: 26711182 - Association between DNMT3A mutations and prognosis of adults with de novo acute myeloid leukemia: a systematic review and meta-analysis.
Tie R, Zhang T, Fu H, Wang L, Wang Y, He Y, Wang B, Zhu N, Fu S, Lai X, Shi J, Huang H. Tie R, et al. PLoS One. 2014 Jun 17;9(6):e93353. doi: 10.1371/journal.pone.0093353. eCollection 2014. PLoS One. 2014. PMID: 24936645 Free PMC article. Review. - [Functional role of DNMT3A mutation in acute myeloid leukemia].
Koya J, Kurokawa M. Koya J, et al. Rinsho Ketsueki. 2018;59(5):602-610. doi: 10.11406/rinketsu.59.602. Rinsho Ketsueki. 2018. PMID: 29877252 Review. Japanese.
Cited by
- A Case of ALK-Positive Anaplastic Large Cell Lymphoma of the Male Breast.
Wang X, Jia Z, Li J, Yang H, Sun X, Liu Y. Wang X, et al. Int Med Case Rep J. 2023 Nov 17;16:747-755. doi: 10.2147/IMCRJ.S434109. eCollection 2023. Int Med Case Rep J. 2023. PMID: 38020577 Free PMC article. - Clonal haematopoiesis and dysregulation of the immune system.
Belizaire R, Wong WJ, Robinette ML, Ebert BL. Belizaire R, et al. Nat Rev Immunol. 2023 Sep;23(9):595-610. doi: 10.1038/s41577-023-00843-3. Epub 2023 Mar 20. Nat Rev Immunol. 2023. PMID: 36941354 Free PMC article. Review. - DNMT3A low-expression is correlated to poor prognosis in childhood B-ALL and confers resistance to daunorubicin on leukemic cells.
Li W, Liu S, Wang C, Cui L, Zhao X, Liu W, Zhang R, Li Z. Li W, et al. BMC Cancer. 2023 Mar 18;23(1):255. doi: 10.1186/s12885-023-10724-6. BMC Cancer. 2023. PMID: 36934225 Free PMC article. - Epigenetic regulation in hematopoiesis and its implications in the targeted therapy of hematologic malignancies.
Zhao A, Zhou H, Yang J, Li M, Niu T. Zhao A, et al. Signal Transduct Target Ther. 2023 Feb 17;8(1):71. doi: 10.1038/s41392-023-01342-6. Signal Transduct Target Ther. 2023. PMID: 36797244 Free PMC article. Review. - Clinical Implication of DNMT3A and TET2 Genes Mutations in Cytogenetically Normal Acute Myeloid Leukemia.
Aref S, Sallam N, Abd Elaziz S, Salama O, Al Ashwah S, Ayed M. Aref S, et al. Asian Pac J Cancer Prev. 2022 Dec 1;23(12):4299-4305. doi: 10.31557/APJCP.2022.23.12.4299. Asian Pac J Cancer Prev. 2022. PMID: 36580013 Free PMC article.
References
- Renneville A, Boissel N, Nibourel O, et al. Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French Association. Leukemia. 2012;26(6):1247–1254. - PubMed
- Gale RE, Lamb K, Allen C, et al. Simpson’s paradox and the impact of different DNMT3A mutations on outcome in younger adults with acute myeloid leukemia. J Clin Oncol. 2015;33(18):2072–2083. - PubMed
- Yan XJ, Xu J, Gu ZH, et al. Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia. Nat Genet. 2013;43(4):309–315. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical